Reading MRVI? Track it free: the weekly brief, plus an alert if the thesis breaks. No credit card.
Track MRVI free→Reading MRVI? Track it free: the weekly brief, plus an alert if the thesis breaks. No credit card.
Track MRVI free→QuarterlyIQ Insights · MRVI
Material updates from SEC filings (8-K, 10-Q, 10-K) ranked by impact, with no firehose noise.
Termination of a Material Definitive Agreement. On June 2, 2026, the parties terminated the Prior Credit Agreement in connection with the Borrower’s prepayment in full of all outstanding borrowings and accrued interest thereunder.
Entry into a Material Definitive Agreement. On June 2, 2026, Maravai Intermediate Holdings, LLC (the “Borrower”) and Maravai Topco Holdings, LLC (“Topco”), each a consolidated subsidiary controlled by Maravai LifeSciences Holdings, Inc., entered into a Credit Agreement (the “New Credit Agreement”) with certain lenders and issuing banks party thereto and BSP Agency, LLC, as administrative agent and collateral agent. The New Credit Agreement provides the Borrower with a $150.0 million term loan…
Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet arrangement of a Registrant. The information set forth above in
of this Form 8-K and the Exhibit 99.1 attached hereto shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended (the “Securities Act”), or the Exchange Act, except as expressly set forth by specific reference in such filing.
of this Form 8-K and the Exhibit 99.1 attached hereto shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended (the “Securities Act”), or the Exchange Act, except as expressly set forth by specific reference in such filing.
of this Form 8-K and the Exhibit 99.1 attached hereto shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended (the “Securities Act”), or the Exchange Act, except as expressly set forth by specific reference in such filing.
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On October 21, 2025, as part of Maravai LifeSciences Holdings, Inc.’s (the “ Company ”) efforts to rationalize the size of its Board of Directors (the “ Board ”) and reduce administrative costs, Benjamin Daverman, Jessica Hopfield, PhD, and Murali Prahalad, PhD each agreed to voluntarily resign from the Board effective as of the close of business o…
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On August 7, 2025, the Company’s Board of Directors eliminated the positions held by Rebecca Buzzeo, Executive Vice President and Chief Commercial Officer of the Company, and Pete Leddy, Ph.D., Executive Vice President and Chief Administrative Officer of the Company. As a result, Ms. Buzzeo’s last day of employment with the Company is expected to b…
Costs Associated with Exit or Disposal Activities. On August 11, 2025, the Company announced an organizational restructuring, including a workforce reduction, to reduce operating costs. The workforce reduction, which is being implemented as part of a strategic cost-reduction initiative, was committed to by management on August 8, 2025 and is expected to impact approximately 25% of the Company’s workforce. In connection with the workforce reduction, the Company currently estimates it will incu…
of this Form 8-K and the Exhibit 99.1 attached hereto shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended (the “Securities Act”), or the Exchange Act, except as expressly set forth by specific reference in such filing.
Changes in Registrant’s Certifying Accountant. On July 16, 2025 (the “ Approval Dat e”), the Audit Committee (the “ Audit Committee ”) of the Board of Directors of Maravai LifeSciences Holdings, Inc. (the “ Company ”) approved the appointment of Deloitte & Touche LLP (“ Deloitte ”) as the independent registered public accounting firm for the Company for the fiscal year ending December 31, 2025, effective immediately. In addition, on the Approval Date, the Audit Committee approved the dismissa…
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. Chief Financial Officer Succession On June 22, 2025, the Board of Directors of Maravai LifeSciences Holdings, Inc. (the “ Company ”) appointed Rajesh Asarpota as Chief Financial Officer of the Company, effective June 30, 2025 (the “ Effective Date ”). Mr. Asarpota will succeed Kevin Herde in the role. In order to enable a smooth transition of his r…
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. Chief Executive Officer Succession On June 8, 2025, the Board of Directors (the “ Board ”) of Maravai LifeSciences Holdings, Inc. (the “ Company ”) appointed Bernd Brust as Chief Executive Officer (“ CEO ”) of the Company, effective immediately, succeeding William E. Martin, III. In addition, effective as of June 8, 2025, Mr. Martin resigned from t…
of this Form 8-K and the Exhibit 99.1 attached hereto shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended (the “Securities Act”), or the Exchange Act, except as expressly set forth by specific reference in such filing.
shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing. Forward-Looking Statements This Current Report on Form 8-K contains “forward-looking statements” within the meanin…
of this Form 8-K and the Exhibit 99.1 attached hereto shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended (the “Securities Act”), or the Exchange Act, except as expressly set forth by specific reference in such filing.
Non-Reliance on Previously Issued Financial Statements or a Related Audit Report or Completed Interim Review. (a) On March 17, 2025, the Audit Committee of the Board of Directors of the Company (the “Audit Committee”) concluded that the Company’s interim financial statements and related disclosures included in the Company’s Quarterly Reports on Form 10-Q for the fiscal quarters ended June 30, 2024 (“Q2 2024”), and September 30, 2024 (“Q3 2024”), and as of and for the interim periods ended Jun…
Results of Operations and Financial Condition. On February 25, 2025, Maravai LifeSciences Holdings, Inc. (the “Company”) issued a press release (the “February 2025 Press Release”) announcing, among other things, that it will be delaying its earnings release and call previously scheduled for February 25, 2025, because it requires additional time to complete its financial close process. The Company intends to file a Form 12b-25, Notification of Late Filing, with the U.S. Securities and Exchange…
General market headlines, full earnings-call transcripts, and macro and sector developments flagged when they directly affect this stock are on the way. Today this tab covers SEC filings.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.